4-guanidinobenzoate has been researched along with Obesity in 1 studies
*Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamagami, K; Hiyoshi, H; Ikeda, Z; Ishihara, Y; Itono, S; Kakegawa, K; Kikuchi, F; Kitazaki, T; Maekawa, T; Oki, H; Sasaki, M; Tohyama, K; Tsuchimori, K; Watanabe, M; Yashiro, H | 1 |
1 other study(ies) available for 4-guanidinobenzoate and Obesity
| Article | Year |
|---|---|
Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity.
Topics: Animals; Benzoates; Enteropeptidase; Guanidines; Mice; Mice, Obese; Obesity; Rats | 2022 |